• Roberta Battini, Manuela Casarano, Giuseppina Sgandurra, Ilaria Olivieri, Roberta Di Pietro, Domenico M Romeo, Eugenio Mercuri, and Giovanni Cioni.
• Department of Developmental Neuroscience, IRCCS Fondazione Stella Maris, Pisa, Italy. Electronic address: r.battini@fsm.unipi.it.
• Eur. J. Paediatr. Neurol. 2014 Nov 1; 18 (6): 698-703.

BackgroundMovement Disorder-Childhood Rating Scale (MD-CRS) is a new tool for assessment of movement disorders during developmental age.AimIn this study we evaluated a cohort of 47 patients affected by dyskinetic cerebral palsy and treated with anticholinergic drug (trihexyphenidyl) over one year in order to verify the responsiveness of the new scale.MethodsThe participants were divided into two groups according to their age (0-3 years; 4-18 years) and were evaluated using MD-CRS 0-3 or MD-CRS 4-18 at baseline, i.e., before starting pharmacological treatment (T0), after 6 (T1) and 12 months (T2) of treatment. Univariate repeated measures ANOVA with a Greenhouse-Geisser correction was performed to analyse the scale responsiveness for the three indexes (e.g., Index I, Index II and Global Index) in each group with time (T0, T1 and T2). In addition, Bonferroni test was performed to identify the source of significant differences among means.ResultsSignificant differences were found between time points (T1 vs T0, T2 vs. T0 and T2 vs. T1) in both scales for all indexes with the exception for T2 vs. T1 for Index II in both scales and for T2 vs. T1 for the Global Index in the older age group. There was not significant correlation between observed changes in the scores and age of children, either for MD-CRS 0-3 or MD-CRS 4-18.ConclusionsOur results suggest that MD-CRS is a suitable tool to detect changes and could be used as outcome measure for clinical trials. Further studies will be necessary to prove the efficacy of trihexyphenidyl for dyskinetic cerebral palsy.Copyright © 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

22 keywords...

hide…